Protamine sulphate for heparin reversal in percutaneous cardiac interventions: a systematic review and meta-analysis of randomized controlled trials
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04369-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Elsayed Balbaa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Alexandria University, Alexandria, Egypt. elsayedbalbaa.med@gmail.com. Hauptthemen laut MEDLINE: Protamines, Heparin Antagonists, Heparin, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexandria University.
Abstract (Originalsprache)
Vascular complications after percutaneous cardiac interventions are a significant cause of morbidity that affects post-procedural prognosis. Data about the efficacy and safety of routine protamine sulphate to prevent these complications remain scarce. Hence, we aim to assess the efficacy and safety of routine protamine sulphate use for heparin reversal in patients undergoing percutaneous cardiac interventions. We systematically searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) until September 2024. The RCTs’ quality was assessed using the Cochrane tool (RoB 2). Using R, we pooled dichotomous outcomes using risk ratios (RR) and continuous outcomes using mean differences (MD), both along the corresponding 95% Confidence interval (CI). PROSPERO ID: (CRD42024593002). Six RCTs with 1,076 patients were eligible. Hemostasis success was significantly higher in the protamine group (RR, 1.06; 95% CI [1.01–1.10]; P = 0.01), and the length of hospital stay was significantly shorter (MD, -0.46; 95% CI [-0.65, -0.26]; P < 0.01). There was no significant difference between both groups in stroke (RR, 0.60; 95% CI [0.18–2.03]; P = 0.41), major bleeding ( P = 0.25), minor bleeding ( P = 0.11), life-threatening bleeding ( P = 0.65), time to ambulation ( P = 0.13), all-cause mortality ( P = 0.92), hematoma/pseudoaneurysm ( P = 0.92), and major vascular complications ( P = 0.70). While protamine improved hemostasis success, its effect on reducing bleeding events and time to ambulation was insignificant. Also, reducing the length of hospital stay in the protamine group highlights its potential clinical benefit. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Alexandria University, Alexandria, Egypt. elsayedbalbaa.med@gmail.com.
- Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Faculty of Medicine, Al-Azhar University, Asyut, Egypt.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Internal Medicine, Rosalind Franklin University of Medicine and Science, Chicago, USA.
Förderung
- Alexandria University
Zitieren
APA
Balbaa, E., Gadelmawla, A. F., Tawfik, A. M., Naeem, A., Elbataa, A., Bazzazeh, M., Fatiem, A. R., Ali, K., Altobaishat, O., & Abuelazm, M. (2025). Protamine sulphate for heparin reversal in percutaneous cardiac interventions: a systematic review and meta-analysis of randomized controlled trials. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04369-4
Vancouver
Balbaa E, Gadelmawla AF, Tawfik AM, Naeem A, Elbataa A, Bazzazeh M, et al. Protamine sulphate for heparin reversal in percutaneous cardiac interventions: a systematic review and meta-analysis of randomized controlled trials. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04369-4
BibTeX
@article{Balbaa2025,
author = {Balbaa, Elsayed and Gadelmawla, Ahmed Farid and Tawfik, Abdelrahman M and Naeem, Ahmed and Elbataa, Ahmed and Bazzazeh, Mohammad and Fatiem, Ahmed Ramadan and Ali, Khaled and Altobaishat, Obieda and Abuelazm, Mohamed},
title = {Protamine sulphate for heparin reversal in percutaneous cardiac interventions: a systematic review and meta-analysis of randomized controlled trials},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04369-4}
}
EUVIMED